Chinese pharmaceutical firms are now leading the charge in new‑drug launches. In 2025, more than 85 % of the innovative medicines approved domestically were home‑grown, with 38 out of 47 new chemical drugs and 21 out of 23 biologics developed in China. The country’s R&D engine is also gaining global clout: its share of early‑stage pipelines for next‑generation therapies such as antibody‑drug conjugates and multispecific antibodies has risen to around 50 % of the world total, and four of the eleven first‑in‑class drugs approved this year were Chinese inventions. Business‑development activity hit a record, with licensing deals worth over $130 billion across more than 150 transactions. The government is backing the surge with faster review pathways, Four fast‑track channels – breakthrough, conditional, priority and special approvals – are being used to push critical medicines to patients faster, stronger data‑protection rules and a new catalogue that welcomes foreign investors in innovative drug manufacturing. Yet insiders warn that pricing and reimbursement systems still lag behind, threatening a sustainable innovation cycle. Overall, China has moved from a follower to a co‑leader in global biomedical innovation, reshaping the industry landscape.
Read more